In contrast, treatment with the GLP-1 receptor agonist liraglutide yielded a small improvement in kidney function at the end of the follow-up period [89], and in two large-scale trials, the use of SGLT2 inhibitors was accompanied by a meaningful and durable improvement in glomerular function and a reduction in the risk of serious adverse renal events [56, 58]
Good communication and regular check-ins with healthcare professionals are very important when using semaglutide treatment
Pharmaceutical-grade drugs have approved NDC numbers, batch-level FDA oversight, and formal recall mechanisms
In this Review, we summarize the current clinical evidence for GLP-1 receptor agonists and cancer risk, including thyroid, pancreatic, gastrointestinal, and hormone-dependent malignancies
Diabetes 2025;74(S1):202
Refreshing Flavor: Delight in the smooth taste of melon with every sip